Show simple item record

dc.contributor.authorBracarda, Sen_US
dc.contributor.authorNegrier, Sen_US
dc.contributor.authorCasper, Jen_US
dc.contributor.authorPorta, Cen_US
dc.contributor.authorSchmidinger, Men_US
dc.contributor.authorLarkin, Jen_US
dc.contributor.authorGross Goupil, Men_US
dc.contributor.authorEscudier, Ben_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2017-04-13T09:40:21Z
dc.date.issued2017-03en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28044472en_US
dc.identifier.citationExpert Rev Anticancer Ther, 2017, 17 (3), pp. 227 - 233en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/587
dc.identifier.eissn1744-8328en_US
dc.identifier.doi10.1080/14737140.2017.1276830en_US
dc.description.abstractINTRODUCTION: Currently, sunitinib is a standard of care in first-line treatment for metastatic renal cell carcinoma (mRCC). However, with the standard 4/2 schedule (sunitinib 50 mg/day; 4 consecutive weeks on treatment; 2 weeks' rest), 50% of patients require dose reductions to mitigate toxicity, highlighting the need to investigate alternative dosing schedules that improve tolerability without compromising efficacy. Areas covered: We present a concise critical review of published studies comparing the efficacy and safety of the 4/2 and 2/1 schedule (2 weeks on treatment; 1 week rest) for sunitinib. While all studies evaluating the 2/1 schedule have a low level of evidence, the results indicate that the 2/1 schedule improves tolerability compared with the 4/2 schedule, including significant reductions in the incidence of specific adverse events. It was not possible to make any definitive conclusions regarding efficacy due to methodologic limitations of these studies. Expert commentary: In the absence of strong evidence supporting the safety and efficacy of the 2/1 schedule, we recommend that patients should be initiated on sunitinib therapy with the standard 4/2 schedule and only be switched to the 2/1 schedule after the development of dose-limiting toxicities from weeks 3-4 (cycle 1) of the 4/2 schedule cycle.en_US
dc.format.extent227 - 233en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectAngiogenesis inhibitorsen_US
dc.subjectdose scheduleen_US
dc.subjectrenal cell carcinomaen_US
dc.subjectstandard of careen_US
dc.subjectsunitiniben_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectCarcinoma, Renal Cellen_US
dc.subjectDose-Response Relationship, Drugen_US
dc.subjectDrug Administration Scheduleen_US
dc.subjectHumansen_US
dc.subjectIndolesen_US
dc.subjectKidney Neoplasmsen_US
dc.subjectNeoplasm Metastasisen_US
dc.subjectPyrrolesen_US
dc.subjectResearch Designen_US
dc.subjectSunitiniben_US
dc.titleHow clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1080/14737140.2017.1276830en_US
rioxxterms.licenseref.startdate2017-03en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfExpert Rev Anticancer Theren_US
pubs.issue3en_US
pubs.notes12 monthsen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume17en_US
pubs.embargo.terms12 monthsen_US
icr.researchteamMelanoma and Kidney Canceren_US
dc.contributor.icrauthorLarkin, Jamesen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record